| Overview |
| bs-11676R-APC |
| UCHL3 Polyclonal Antibody, APC Conjugated |
| WB, IF(IHC-P), IF(IHC-F), IF(ICC) |
| Human, Rat |
| Mouse, Chicken |
| Specifications |
| APC |
| Rabbit |
| KLH conjugated synthetic peptide derived from human UCHL3 |
| 133-230/230 |
| Polyclonal |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| Aqueous buffered solution containing 0.01M TBS (pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
| Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target |
| 7347 |
| P15374 |
| Cytoplasm |
| Ubiquitin carboxyl-terminal hydrolase isozyme L3; Ubiquitin thioesterase L3; Ubiquitin thiolesterase; Ubiquitin thiolesterase L3; UCH L3; UCH-L3; UCHL3; UCHL3_HUMAN. |
| UCH-L1 is a member of a gene family whose products hydrolyze small C-terminal adducts of ubiquitin to generate the ubiquitin monomer. Expression of UCH-L1 is highly specific to neurons and to cells of the diffuse neuroendocrine system and their tumors. UCH-L1 is expressed in brain neurons. Examination of specific brain regions reveals expression in all areas tested, particularly in the substantia nigra. UCH-L1 represents 1 to 2% of total soluble brain protein. Its occurrence in Lewy bodies and its function in the proteasome pathway make it a compelling candidate gene in Parkinson disease. The gene which encodes UCH-L1 maps to human chromosome 4p14. The 230 amino acid human UCH-L3 protein is 54% identical to that of UCH-L1. UCH-L3 is the predominant thiol protease and has high-affinity binding sites for ubiquitin. |
| Application Dilution |
| WB |
1:300-5000 |
| IF(IHC-P) |
1:50-200 |
| IF(IHC-F) |
1:50-200 |
| IF(ICC) |
1:50-200 |
Powered by Bioz